Products
Becotatug Biosimilar Monoclonal Antibody (EGFR) for Research
Cat No.: GMP-Bios-INN-1096
Anti-EGFR/ERBB1/HER1 therapeutic antibody (Pre-made Becotatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Becotatug (development code JMT101) is a monoclonal antibody targeting EGFR. It is developed by CSPC Pharmaceutical Group and Shanghai Jinmante Biotechnology for cancers, non-small cell lung cancer, metastatic cancers. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1096-1mg | 1mg | 3090 |
| GMP-Bios-INN-1096-10mg | 10mg | |
| GMP-Bios-INN-1096-100mg | 100mg | |
| GMP-Bios-INN-1096-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Becotatug biosimilar, Whole mAb, Anti-EGFR/ERBB1/HER1 Antibody: Anti-EGFR/Epidermal growth factor receptor/Proto-oncogene c-ErbB-1/Receptor tyrosine-protein kinase erbB-1 therapeutic antibody |
| INN Name | Becotatug |
| Target | EGFR/ERBB1/HER1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology |
| Conditions Approved | na |
| Conditions Active | Cancers;Non-small cell lung cancer;Metastatic cancers |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
